“…Distant metastases of OSCC after treatment are common in the lung, bone, liver, brain and other sites (Liu, Bhayani, Kuchta, Galloway, & Fundakowski, ). Data from academic cancer centres and retrospective studies have yielded varying results about the distant metastasis rates at each site, and the population‐based estimates of the prognosis of newly diagnosed OSCC patients with distant metastases are insufficient (Aires, Lin, Matos, Kulcsar, & Cernea, ; Garavello, Ciardo, Spreafico, & Gaini, ; Hasegawa et al, ; Hosni et al, ; Krstevska, Stojkovski, & Zafirova‐Ivanova, ; Sakamoto et al, ; Spector et al, ; Sumioka et al, ; Takahashi et al, ; Takes et al, ; Yao et al, ). A total of 5.7% patients with TSCC, which is the most common type of OSCC, had distant metastases and a lower 5‐year survival rate than patients with other types of OSCC (Osaki, Kimura, Tatemoto, Yamamoto, & Yoneda, ; Young et al, ).…”